Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.39 +2.6%	$0.43	$0.24 ▼ $2.53	$21.97M	0.91	915,016 shs	517,686 shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
ITOS iTeos Therapeutics	$10.07 -1.1%	$9.04	$4.80 ▼ $18.13	$389.63M	1.49	691,647 shs	452,783 shs
SBTX Silverback Therapeutics	$16.52 -1.4%	$14.84	$2.80 ▼ $8.97	$595.68M	0.6	337,931 shs	881,491 shs
VOR Vor Biopharma	$2.67 +39.8%	$0.49	$0.13 ▼ $3.20	$333.64M	2.04	4.43 million shs	49.20 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	+1.58%	-2.53%	-19.90%	+44.73%	-70.76%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
ITOS iTeos Therapeutics	-0.98%	+1.00%	-0.98%	+99.80%	-28.15%
SBTX Silverback Therapeutics	0.00%	-9.23%	+14.01%	+28.76%	+81.54%
VOR Vor Biopharma	+41.64%	+64.81%	+1,093.03%	+385.45%	+194.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.7275 of 5 stars	3.3	2.0	0.0	0.0	3.1	2.5	0.6
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	3.1841 of 5 stars	4.1	2.0	0.0	0.0	1.4	3.3	0.6
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	3.9713 of 5 stars	4.3	5.0	0.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.50	Moderate Buy	$5.00	1,195.34% Upside
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
ITOS iTeos Therapeutics	2.14	Hold	$15.86	57.47% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	110.81% Upside

Current Analyst Ratings Breakdown

Latest SBTX, BCAB, GRCL, ITOS, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00
5/13/2025	ITOS iTeos Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $8.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	2.05	N/A	N/A	$0.25 per share	1.54
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
ITOS iTeos Therapeutics	$35M	11.01	N/A	N/A	$16.16 per share	0.62
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.22	N/A	N/A	N/A	N/A	-373.47%	-116.55%	8/6/2025 (Estimated)
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SBTX, BCAB, GRCL, ITOS, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	BCAB BioAtla	-$0.28	-$0.29	-$0.01	-$0.26	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	2.35	2.35
GRCL Gracell Biotechnologies	0.02	7.73	7.73
ITOS iTeos Therapeutics	N/A	14.13	14.13
SBTX Silverback Therapeutics	N/A	67.87	67.87
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
GRCL Gracell Biotechnologies	N/A
ITOS iTeos Therapeutics	97.16%
SBTX Silverback Therapeutics	74.89%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.50%
GRCL Gracell Biotechnologies	28.00%
ITOS iTeos Therapeutics	12.50%
SBTX Silverback Therapeutics	34.40%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.42 million	51.70 million	Optionable
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

SBTX, BCAB, GRCL, ITOS, and VOR Headlines

Recent News About These Companies

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63

1 hour ago | americanbankingnews.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6 at 3:56 PM | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5 at 2:37 AM | marketbeat.com

HC Wainwright Predicts Weaker Earnings for Vor Biopharma

July 4, 2025 | americanbankingnews.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

HC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"

July 2, 2025 | americanbankingnews.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30, 2025 | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30, 2025 | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30, 2025 | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

Vor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

June 27, 2025 | marketbeat.com

Vor, with new CEO, changes course to target autoimmune disease

June 26, 2025 | biopharmadive.comB

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

June 26, 2025 | bioworld.comB

Vor Biopharma Insider Trading Activity | NASDAQ:VOR | Benzinga

June 26, 2025 | benzinga.com

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

June 26, 2025 | fiercepharma.comF

Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy

June 26, 2025 | msn.com

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

June 26, 2025 | marketbeat.com

Vor Biopharma: Vor Bio Announces $175 Million Private Placement

June 26, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, BCAB, GRCL, ITOS, and VOR Company Descriptions

BioAtla NASDAQ:BCAB

$0.39 +0.01 (+2.63%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$0.39 +0.00 (+0.78%)

As of 07/7/2025 06:37 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

iTeos Therapeutics NASDAQ:ITOS

$10.07 -0.11 (-1.08%)

As of 07/7/2025 04:00 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Silverback Therapeutics NASDAQ:SBTX

$16.52 -0.23 (-1.37%)

As of 07/3/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Vor Biopharma NYSE:VOR

$2.67 +0.76 (+39.79%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$2.80 +0.13 (+5.02%)

As of 07/7/2025 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time